Loading stock data…
Loading stock data…
US$6.33
Get one email when AARD crosses your level. Checked every 15 minutes during market hours.
▼ -0.34 (-5.10%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
57.8
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
0.53
Bullish momentumMACD above its signal line (0.41).
50-day average
4.87
Price aboveShort-term trend reference.
200-day average
9.07
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel small-molecule therapies for metabolic and hunger-associated disorders. The company focuses on activating innate homeostatic pathways, particularly through selective targeting of Bitter Taste Receptors (TAS2Rs) in the gut to modulate appetite and related metabolic processes. Its lead product candidate, ARD-101, is an oral, gut-restricted small-molecule agonist of specific TAS2Rs bei…
aardvarktherapeutics.com5 strong buy · 6 buy · 5 hold · 2 sell · 0 strong sell (18 analysts, 2026-07-01)
6 strong buy · 6 buy · 4 hold · 2 sell · 0 strong sell (18 analysts, 2026-06-01)
7 strong buy · 6 buy · 5 hold · 0 sell · 0 strong sell (18 analysts, 2026-05-01)
7 strong buy · 6 buy · 5 hold · 0 sell · 0 strong sell (18 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-05-07 | -0.91 | -0.99 | ✗ Miss |
| 2026-03-23 | -0.83 | -0.81 | ✓ Beat |
| 2026-02-12 | 1.03 | 1.07 | ✓ Beat |
| 2025-11-07 | 0.6 | 0.69 | ✓ Beat |
| 2025-10-23 | -0.3 | -0.19 | ✓ Beat |
| 2025-08-13 | -0.6 | -0.66 | ✗ Miss |
| 2025-05-14 | -0.61 | -0.71 | ✗ Miss |
Companies in the same industry, via Finnhub